Unlocking the Potential of LOXL3: A Variant of the LoxL3 gene

Target Name: LOXL3

NCBI ID: G84695

LOXL3

Unlocking the Potential of LOXL3: A Variant of the LoxL3 gene

Introduction

The LoxL3 gene, located on chromosome 6p21.1, has been extensively studied for its role in various cellular processes. In particular, LoxL3 has been shown to play a crucial role in regulating cell proliferation and differentiation, DNA repair, and apoptosis. More importantly Yes, LoxL3 has been implicated in numerous diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. This has led to a growing interest in developing LoxL3-based therapeutics for these diseases. In this article, we will explore the potential of LoxL3 as a drug target and highlight its implications for future medical research.

LOXL3 Variants and Their Implications

LOXL3, the gene encoding the homeobox gene, is a member of the P160 gene family. P160 genes are involved in the development and maintenance of various tissues, including neural cells, epithelial cells, and immune cells. LoxL3, specifically, has been shown to promote cell proliferation and differentiate into immortal cell lines.

However, LoxL3 variants have been implicated in the development and progression of various diseases. For example, a missense variant, LoxL3-ASP2, has been linked to the development of colon cancer. Inactivated LoxL3 has also been shown to contribute to the development of neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease. Additionally, LoxL3 variants have been implicated in autoimmune diseases, such as rheumatoid arthritis and psoriasis.

The Potential of LoxL3 as a Drug Target

The potential of LoxL3 as a drug target is based on its involvement in various cellular processes and its association with the development of various diseases. LoxL3 has been shown to play a role in regulating cell proliferation and apoptosis, which are critical processes for cancer and neurodegenerative disorders.

One of the most promising aspects of LoxL3 as a drug target is its potential to target small molecules that can inhibit its activity. For example, LoxL3 has been shown to be sensitive to inhibitors such as 5-fluorouracil (5-FU) and taxol, which are commonly used in cancer treatment. Additionally, LoxL3 has been shown to be responsive to small molecules that can modulate its gene expression, such as DNA methylation and histone modification.

Another approach to targeting LoxL3 is to use small molecules that can modulate its activity in cell-cell interactions. For example, LoxL3 has been shown to play a role in regulating cell-cell adhesion, which is critical for the development of various tissues and organs . Thus, small molecules that can modulate LoxL3 activity in cell-cell interactions may be useful for targeting LoxL3 in various diseases.

Targeting LoxL3: A Review of Small Molecules

Several small molecules have been shown to be capable of modulating LoxL3 activity. One of the most promising classes of small molecules is the DNA methylation inhibitors. These molecules can bind to the promoter region of LoxL3 and prevent it from being repressed by DNA methylation. Such molecule is 5-methylisocaprolactone (5-MIC), which has been shown to inhibit LoxL3 activity in cell-cell interactions and promote its expression in various tissues.

Another class of small molecules that may be useful for targeting LoxL3 is the histone modification inhibitors. These molecules can bind to the histone modifications on LoxL3 and prevent them from modifying its activity. One such molecule is colchicine, which is a natural compound that has been shown to inhibit LoxL3 activity in various cell types.

In addition, small molecules that can modulate LoxL3 activity in cell-cell interactions may also be useful for targeting LoxL3. These molecules can include inhibitors of

Protein Name: Lysyl Oxidase Like 3

Functions: Protein-lysine 6-oxidase that mediates the oxidation of peptidyl lysine residues to allysine in target proteins (PubMed:17018530, PubMed:28065600). Catalyzes the post-translational oxidative deamination of peptidyl lysine residues in precursors of elastin and different types of collagens, a prerequisite in the formation of cross-links between collagens and elastin (PubMed:17018530). Required for somite boundary formation by catalyzing oxidation of fibronectin (FN1), enhancing integrin signaling in myofibers and their adhesion to the myotendinous junction (MTJ) (By similarity). Acts as a regulator of inflammatory response by inhibiting differentiation of naive CD4(+) T-cells into T-helper Th17 or regulatory T-cells (Treg): acts by interacting with STAT3 in the nucleus and catalyzing both deacetylation and oxidation of lysine residues on STAT3, leading to disrupt STAT3 dimerization and inhibit STAT3 transcription activity (PubMed:28065600). Oxidation of lysine residues to allysine on STAT3 preferentially takes place on lysine residues that are acetylated (PubMed:28065600). Also able to catalyze deacetylation of lysine residues on STAT3 (PubMed:28065600)

The "LOXL3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LOXL3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets